Nontoxic, fiscally responsible, future of oncology: Could it be beginning in the third world?

Journal of Pediatric Hematology/Oncology

Volumn 33, Issue 1, 2011, Pages 1-3

  Klement, Giannoula Lakka ^a   Kamen, Barton A ^b  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; HISTONE DEACETYLASE INHIBITOR; IMATINIB; METHOTREXATE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; PROTEASOME INHIBITOR; TAXANE DERIVATIVE; THALIDOMIDE; VINBLASTINE; VINCA ALKALOID; VINCRISTINE;

ACUTE LYMPHOCYTIC LEUKEMIA; CANCER CHEMOTHERAPY; CHILDHOOD CANCER; HEALTH CARE POLICY; MAXIMUM TOLERATED DOSE; ONCOLOGY; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEVELOPING COUNTRIES; HUMANS; MAXIMUM TOLERATED DOSE; MEDICAL ONCOLOGY; NEOPLASMS;

EID: 78650796469     PISSN: 10774114     EISSN: 15363678     Source Type: Journal    
DOI: 10.1097/MPH.0b013e3182024918     Document Type: Review

References (34)

1. Fousseiny T, Diawara M, Pasquier E, et al. Children treated with metronomic chemotherapy in a low-income country: METROMALI- 01. J Pediatr Hematol Oncol. 2011;33:31-34.
2. Klement G, Baruchel S, Rak J, et al. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest. 2000; 105:R15-24.
3. Browder T, Butterfield CE, Kraling BM, et al. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res. 2000;60:1878-1886.
4. Hanahan D, Bergers G, Bergsland E. Less is more, regularly: Metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J Clin Invest. 2000;105:1045-1047.
5. Folkman J, Kalluri R. Cancer without disease. Nature. 2004; 427:787.
6. Kerbel RS, Kamen BA. The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer. 2004;4:423-436.
7. Kerbel RS, Klement G, Pritchard KI, et al. Continuous low-dose anti-angiogenic/metronomic chemotherapy: from the research laboratory into the oncology clinic. Ann Oncol. 2002;13: 12-15.
8. Hafner C, Reichle A, Vogt T. New indications for established drugs: Combined tumor-stroma-targeted cancer therapy with PPAR agonists, COX-2 inhibitors, mTOR antagonists and metronomic chemotherapy. Curr Cancer Drug Targets. 2005; 5:393-419.
9. Ghirighelli F, Menard C, Puig PE, et al. Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol Immunother. 2007;56:641-648.
10. Miller KD, Sweeney CJ, Sledge GW Jr. Redefining the target: Chemotherapeutics as antiangiogenics. J Clin Oncol. 2001;19: 1195-1206.
11. Reynolds AR. Potential relevance of bell-shaped and u-shaped dose-responses for the therapeutic targeting of angiogenesis in cancer. Dose Response. 2009;8:253-284.
12. Wang J, Lou P, Lesniewski R, et al. Paclitaxel at ultra low concentrations inhibits angiogenesis without affecting cellular microtubule assembly. Anticancer Drugs. 2003;14:13-19.
13. Bocci G, Nicolaou KC, Kerbel RS. Protracted low-dose effects on human endothelial cell proliferation and survival in vitro reveal a selective antiangiogenic window for various chemotherapeutic drugs. Cancer Res. 2002;62:6938-6943.
14. Vacca A, Iurlaro M, Ribatti D, et al. Antiangiogenesis is produced by nontoxic doses of vinblastine. Blood. 1999;94: 4143-4155.
15. Guidolin D, Vacca A, Nussdorfer GG, et al. A new image analysis method based on topological and fractal parameters to evaluate the angiostatic activity of docetaxel by using the Matrigel assay in vitro. Microvasc Res. 2004;67:117-124.
16. Ingber DE. Tensegrity II: how structural networks influence cellular information processing networks. J Cell Sci. 2003;116 (Pt 8):1397-1408.
17. Ingber DE, Tensegrity I. Cell structure and hierarchical systems biology. J Cell Sci. 2003;116(Pt 7):1157-1173.
18. Klement G, Huang P, Mayer B, et al. Differences in therapeutic indexes of combination metronomic chemotherapy and an anti- VEGFR-2 antibody in multidrug-resistant human breast cancer xenografts. Clin Cancer Res. 2002;8:221-232.
19. Ribatti D, Nico B, Mangieri D, et al. In vivo inhibition of human hepatocellular carcinoma related angiogenesis by vinblastine and rapamycin. Histol Histopathol. 2007;22:285-289.
20. Vacca A, Ribatti D, Iurlaro M, et al. Docetaxel versus paclitaxel for antiangiogenesis. J Hematother Stem Cell Res. 2002;11: 103-118.
21. Tran J, Master Z, Yu JL, et al. A role for survivin in chemoresistance of endothelial cells mediated by VEGF. Proc Natl Acad Sci U S A. 2002;99:4349-4354.
22. Kremer JM. Rational use of new and existing disease-modifying agents in rheumatoid arthritis. Ann Intern Med. 2001;134:695-706.
23. Colleoni M, Orlando L, Sanna G, et al. Metronomic low-dose oral cyclophosphamide and methotrexate plus or minus thalidomide in metastatic breast cancer: Antitumor activity and biological effects. Ann Oncol. 2006;17:232-238.
24. El Bary NA, Hashem T, Metwally H, et al. A phase II study of highdose celecoxib and metronomic 'low-dose' cyclophosphamide and methotrexate in patients with relapsed and refractory lymphoma. Hematol Oncol Stem Cell Ther. 2010;3:13-18.
25. Herrlinger U, Rieger J, Steinbach JP, et al. UKT-04 trial of continuous metronomic low-dose chemotherapy with methotrexate and cyclophosphamide for recurrent glioblastoma. J Neurooncol. 2005;71:295-299.
26. Orlando L, Cardillo A, Ghisini R, et al. Trastuzumab in combination with metronomic cyclophosphamide and methotrexate in patients with HER-2 positive metastatic breast cancer. BMC Cancer. 2006;6:225.
27. Wong NS, Buckman RA, Clemons M, et al. Phase I/II trial of metronomic chemotherapy with daily dalteparin and cyclophosphamide, twice-weekly methotrexate, and daily prednisone as therapy for metastatic breast cancer using vascular endothelial growth factor and soluble vascular endothelial growth factor receptor levels as markers of response. J Clin Oncol. 2010;28: 723-730.
28. Brackstone M, Townson JL, Chambers AF. Tumour dormancy in breast cancer: An update. Breast Cancer Res. 2007;9:208.
29. Klareskog L, van der Heijde D, de Jager JP, et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: Double-blind randomised controlled trial. Lancet. 2004;363: 675-681.
30. Kremer JM, Genant HK, Moreland LW, et al. Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: A randomized trial. Ann Intern Med. 2006;144:865-876.
31. Kremer JM, Genovese MC, Cannon GW, et al. Concomitant leflunomide therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate: A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 2002;137:726-733.
32. Kakolyris S, Samonis G, Koukourakis M, et al. Treatment of nonsmall- cell lung cancer with prolonged oral etoposide. Am J Clin Oncol. 1998;21:505-508.
33. Koukourakis MI, Kourousis C, Kamilaki M, et al. Weekly docetaxel and concomitant boost radiotherapy for non-small cell lung cancer: A phase I/II dose escalation trial. Eur J Cancer. 1998;34:838-844.
34. Kamen BA, Glod J, Cole PD. Metronomic therapy from a pharmacologist's view. J Pediatr Hematol Oncol. 2006;28:325-327.